Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Insmed (INSM) Research & Development (2016 - 2026)

Insmed's Research & Development history spans 17 years, with the latest figure at $209.5 million for Q1 2026.

  • Quarterly Research & Development rose 37.3% to $209.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $828.0 million through Mar 2026, up 31.46% year-over-year, with the annual reading at $771.1 million for FY2025, 28.87% up from the prior year.
  • Research & Development came in at $209.5 million for Q1 2026, down from $254.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $254.9 million in Q4 2025 to a low of $84.4 million in Q1 2022.
  • The 5-year median for Research & Development is $146.7 million (2024), against an average of $149.9 million.
  • Year-over-year, Research & Development skyrocketed 122.5% in 2023 and then decreased 25.5% in 2024.
  • Insmed's Research & Development stood at $124.8 million in 2022, then grew by 9.83% to $137.0 million in 2023, then surged by 31.16% to $179.7 million in 2024, then skyrocketed by 41.83% to $254.9 million in 2025, then decreased by 17.82% to $209.5 million in 2026.
  • Per Business Quant, the three most recent readings for INSM's Research & Development are $209.5 million (Q1 2026), $254.9 million (Q4 2025), and $186.4 million (Q3 2025).